Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Phase I Trial Using Interleukin-2 (IL-2) to Expand Regulatory T Cells in Patients With Alzheimer's Disease
Authors not listed
The Methodist Hospital Research Institute · 2019
Abstract
Neuroinflammation is a significant component of Alzheimer disease (AD). Our data demonstrated compromised regulatory T cells (Tregs) phenotype and suppressive function in AD patients, skewing the immune system toward a proinflammatory status and potentially contributing in disease progression. Low dose interleukin-2 (IL-2) is now viewed as a very promising immunoregulatory drug having the capacity to selectively expand and restore functional Tregs. This study is a phase I open-label study to assess subcutaneous interleukin-2 (IL2) safety and potential efficacy as a Treg inducer in AD. 8 Alzheimer dementia patients with mild clinical dementia will be recruited into the study. The baseline cognitive status will be evaluated in these patients. Monthly five-day-courses of subcutaneous IL2 (1MUI/day) will be administered for a total of 4 months. Changes in Tregs from pre to post injections will be measured during the study period. The expected time participants will be in the study is 6 months.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-02 MST
Cite this
APA
Anonymous. (2019). Phase I Trial Using Interleukin-2 (IL-2) to Expand Regulatory T Cells in Patients With Alzheimer's Disease. <em>The Methodist Hospital Research Institute</em>. https://clinicaltrials.gov/study/NCT05821153
Vancouver
Anonymous. Phase I Trial Using Interleukin-2 (IL-2) to Expand Regulatory T Cells in Patients With Alzheimer's Disease. The Methodist Hospital Research Institute. 2019.
BibTeX
@misc{anon2019PhaseI,
title = {Phase I Trial Using Interleukin-2 (IL-2) to Expand Regulatory T Cells in Patients With Alzheimer's Disease},
author = {Anonymous},
journal = {The Methodist Hospital Research Institute},
year = {2019},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
T3D Therapeutics, Inc. 2026
Open access · US-GOV
A Phase 2b/3 Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Evaluate the Safety and Efficacy of T3D-959 in Subjects With Mild-to-Moderate Alzheimer's Disease
Yonsei University 2026
Open access · US-GOV
Efficacy of Lecanemab in Patients With Parkinson's Disease With Coexistent Alzheimer's Disease
US Department of Veterans Affairs 2007
Open access · US-GOV
CSP #546 - A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease (TEAM-AD)
Biruni University 2024
Open access · US-GOV
The Effect of Personalised Pharmaconutrition Therapy on Myosteatosis, Sarcopenia and Prognosis in Patients With Gastric Cancer
Janssen-Cilag, S.A. 2008
Open access · US-GOV
An Observational Epidemiological Study on Evaluation of Sleep Quality in Patients With Mild to Moderate Alzheimer's Disease in Clinical Practice
Aleksandra Stark 2017
Open access · US-GOV